Advances in the management of esophageal cancer

Authors : Bruce D MINSKY

Pages : 3-10

Doi:10.5472/mmj.10059

View : 13 | Download : 9

Publication Date : 2015-09-30

Article Type : Research Paper

Abstract :The management of clinical stage III and IVa esophageal cancer has evolved in the past 2 decades. Based on the Cross trial, neoadjuvant chemoradiation, followed by surgical resection has become standard. For medically inoperable, definitive chemoradiation is most commonly used. The standard radiation dose is 50.4 Gy although trials of doseescalation are ongoing. At the current time, there are no definitive biomarkers to predict response. Keywords: Esophageal cancer, Radiation therapy, Chemotherapy, Dose-escalation
Keywords : Esophageal cancer, Radiation therapy, Chemotherapy, Dose escalation